(Q42993963)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

6

Bernd Jilma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Christa Firbas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Thomas Boehm

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Vera Buerger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Elisabeth Schuller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christoph S Klade

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

9 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

2397-2407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20060945%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of hepatitis C: geographic differences and temporal trends

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Global epidemiology of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

The hepatitis C virus: overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Correlation between virus genotype and chronicity rate in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

CD8 T cell dysfunction during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Development of hepatitis C virus vaccines: challenges and progress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Hepatitis C vaccine: supply and demand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Rapid effector function in CD8+ memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

A step forward in therapy for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Immune response modifiers--mode of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Dose sparing with intradermal injection of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Maternal Neutralizing Antibody and Transmission of Hepatitis C Virus to Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072

PD-1 tempers Tregs in chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.072